Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) traded down 6.7% during mid-day trading on Tuesday following insider selling activity.The stock traded as low as $67.23 and ...

Highlights:,Insider transactions have been observed within Soleno Therapeutics, with key executives reducing personal holdings.,Analysts from multiple firms have adjusted their outlook on the company, ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome.

Congratulations to Soleno Therapeutics and our thanks to them for their work and determination. IPWSO will liaise with Soleno and work with national PWS Associations to highlight the urgent need for, ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, has recently achieved a significant milestone with ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, has recently achieved a significant milestone ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...